Another variant of CAR-T cells directed to ECM components were the above CAR-T cells targeting chondroitin sulfate proteoglycan 4; those CAR-T cells performed fairly well when being released from the HA hydrogel implants in a murine model of post-surgery tumor recurrence [89]. This evidence concerns the gene CSPG4 and neoplasm.